WO2002043794A1 - Improved metering valve and actuator for metered dose inhaler - Google Patents
Improved metering valve and actuator for metered dose inhaler Download PDFInfo
- Publication number
- WO2002043794A1 WO2002043794A1 PCT/GB2001/005297 GB0105297W WO0243794A1 WO 2002043794 A1 WO2002043794 A1 WO 2002043794A1 GB 0105297 W GB0105297 W GB 0105297W WO 0243794 A1 WO0243794 A1 WO 0243794A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- chamber
- valve stem
- canister
- stem
- actuator
- Prior art date
Links
- 229940071648 metered dose inhaler Drugs 0.000 title description 11
- 239000007921 spray Substances 0.000 claims abstract description 36
- 239000000203 mixture Substances 0.000 claims abstract description 34
- 238000009472 formulation Methods 0.000 claims abstract description 33
- 239000000443 aerosol Substances 0.000 claims abstract description 14
- 239000003814 drug Substances 0.000 description 12
- 239000003380 propellant Substances 0.000 description 6
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 229960002052 salbutamol Drugs 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 2
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 2
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000003266 anti-allergic effect Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 description 1
- AKNNEGZIBPJZJG-MSOLQXFVSA-N (-)-noscapine Chemical compound CN1CCC2=CC=3OCOC=3C(OC)=C2[C@@H]1[C@@H]1C2=CC=C(OC)C(OC)=C2C(=O)O1 AKNNEGZIBPJZJG-MSOLQXFVSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- KZDCMKVLEYCGQX-UDPGNSCCSA-N 2-(diethylamino)ethyl 4-aminobenzoate;(2s,5r,6r)-3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;hydrate Chemical compound O.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 KZDCMKVLEYCGQX-UDPGNSCCSA-N 0.000 description 1
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 1
- RPHLQSHHTJORHI-UHFFFAOYSA-N Adrenochrome Chemical compound O=C1C(=O)C=C2N(C)CC(O)C2=C1 RPHLQSHHTJORHI-UHFFFAOYSA-N 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102400000321 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- VQDBNKDJNJQRDG-UHFFFAOYSA-N Pirbuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=N1 VQDBNKDJNJQRDG-UHFFFAOYSA-N 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000001780 adrenocortical effect Effects 0.000 description 1
- 230000003023 adrenocorticotropic effect Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- AKNNEGZIBPJZJG-UHFFFAOYSA-N alpha-noscapine Natural products CN1CCC2=CC=3OCOC=3C(OC)=C2C1C1C2=CC=C(OC)C(OC)=C2C(=O)O1 AKNNEGZIBPJZJG-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000003434 antitussive agent Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- 229940092705 beclomethasone Drugs 0.000 description 1
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- 239000000168 bronchodilator agent Substances 0.000 description 1
- CYDMQBQPVICBEU-UHFFFAOYSA-N chlorotetracycline Natural products C1=CC(Cl)=C2C(O)(C)C3CC4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-UHFFFAOYSA-N 0.000 description 1
- CYDMQBQPVICBEU-XRNKAMNCSA-N chlortetracycline Chemical compound C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-XRNKAMNCSA-N 0.000 description 1
- 229960004126 codeine Drugs 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- ALEXXDVDDISNDU-JZYPGELDSA-N cortisol 21-acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O ALEXXDVDDISNDU-JZYPGELDSA-N 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 229960000265 cromoglicic acid Drugs 0.000 description 1
- IMZMKUWMOSJXDT-UHFFFAOYSA-N cromoglycic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 description 1
- 229960002104 cyanocobalamin Drugs 0.000 description 1
- 235000000639 cyanocobalamin Nutrition 0.000 description 1
- 239000011666 cyanocobalamin Substances 0.000 description 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 229960002069 diamorphine Drugs 0.000 description 1
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- DLNKOYKMWOXYQA-UHFFFAOYSA-N dl-pseudophenylpropanolamine Natural products CC(N)C(O)C1=CC=CC=C1 DLNKOYKMWOXYQA-UHFFFAOYSA-N 0.000 description 1
- 229960002179 ephedrine Drugs 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 229960004943 ergotamine Drugs 0.000 description 1
- OFKDAAIKGIBASY-VFGNJEKYSA-N ergotamine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2C(C3=CC=CC4=NC=C([C]34)C2)=C1)C)C1=CC=CC=C1 OFKDAAIKGIBASY-VFGNJEKYSA-N 0.000 description 1
- XCGSFFUVFURLIX-UHFFFAOYSA-N ergotaminine Natural products C1=C(C=2C=CC=C3NC=C(C=23)C2)C2N(C)CC1C(=O)NC(C(N12)=O)(C)OC1(O)C1CCCN1C(=O)C2CC1=CC=CC=C1 XCGSFFUVFURLIX-UHFFFAOYSA-N 0.000 description 1
- 229960002428 fentanyl Drugs 0.000 description 1
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 description 1
- 229960000676 flunisolide Drugs 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 229960001067 hydrocortisone acetate Drugs 0.000 description 1
- WVLOADHCBXTIJK-YNHQPCIGSA-N hydromorphone Chemical compound O([C@H]1C(CC[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O WVLOADHCBXTIJK-YNHQPCIGSA-N 0.000 description 1
- 229960001410 hydromorphone Drugs 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000001746 injection moulding Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229940039009 isoproterenol Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- LMOINURANNBYCM-UHFFFAOYSA-N metaproterenol Chemical compound CC(C)NCC(O)C1=CC(O)=CC(O)=C1 LMOINURANNBYCM-UHFFFAOYSA-N 0.000 description 1
- HNJJXZKZRAWDPF-UHFFFAOYSA-N methapyrilene Chemical compound C=1C=CC=NC=1N(CCN(C)C)CC1=CC=CS1 HNJJXZKZRAWDPF-UHFFFAOYSA-N 0.000 description 1
- 229960001869 methapyrilene Drugs 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- PLPRGLOFPNJOTN-UHFFFAOYSA-N narcotine Natural products COc1ccc2C(OC(=O)c2c1OC)C3Cc4c(CN3C)cc5OCOc5c4OC PLPRGLOFPNJOTN-UHFFFAOYSA-N 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 229960002657 orciprenaline Drugs 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 229960001802 phenylephrine Drugs 0.000 description 1
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 1
- DLNKOYKMWOXYQA-APPZFPTMSA-N phenylpropanolamine Chemical compound C[C@@H](N)[C@H](O)C1=CC=CC=C1 DLNKOYKMWOXYQA-APPZFPTMSA-N 0.000 description 1
- 229960000395 phenylpropanolamine Drugs 0.000 description 1
- 229960005414 pirbuterol Drugs 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- IYMMESGOJVNCKV-SKDRFNHKSA-N rimiterol Chemical compound C([C@@H]1[C@@H](O)C=2C=C(O)C(O)=CC=2)CCCN1 IYMMESGOJVNCKV-SKDRFNHKSA-N 0.000 description 1
- 229960001457 rimiterol Drugs 0.000 description 1
- 229960002646 scopolamine Drugs 0.000 description 1
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000011885 synergistic combination Substances 0.000 description 1
- 229960000195 terbutaline Drugs 0.000 description 1
- IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 229960001322 trypsin Drugs 0.000 description 1
- 230000003639 vasoconstrictive effect Effects 0.000 description 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D83/00—Containers or packages with special means for dispensing contents
- B65D83/14—Containers for dispensing liquid or semi-liquid contents by internal gaseous pressure, i.e. aerosol containers comprising propellant
- B65D83/44—Valves specially adapted for the discharge of contents; Regulating devices
- B65D83/52—Metering valves; Metering devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
Definitions
- the present invention relates to a metered dose inhaler for delivering a metered amount of a formulation from a pressurized canister carrying a metering valve in which spray producing means are located in the metering valve, in particular in the valve stem of the metering valve, rather than in the actuator.
- Portable devices are widely available to a patients wishing to self-administer therapeutic and preventative medicament formulations to combat the symptoms of respiratory disorders, such as asthma.
- Such devices are generally arranged to dispense a discrete amount of the formulation, (usually in the form of a fluid or particulate medicament entrained in a stream of gas or vapour) into the respiratory passages and are widely referred to as metered dose inhalers.
- a metered dose inhaler comprises two main parts, namely a canister containing the pressurized formulation and an actuator device having a mouth piece for delivering the metered amount of formulation to the user.
- a metered dose inhaler comprises a cylindrical housing which receives a cylindrical canister containing a pressurized medicament formulation.
- the canister is provided with a dispensing metering valve including a metering chamber and a valve stem having an internal conduit which makes a tight push fit engagement into a valve stem block located towards the end portion of the cylindrical housing and adjacent the mouth piece situated at the end of the actuator.
- the user applies a compressive force to the closed end of the canister.
- the internal components of the metering valve are spring-loaded so that a low compressive force is sufficient for the canister to move axially with respect to the valve stem by an amount sufficient for the valve stem to penetrate the canister and cause a metered quantity of formulation to be expelled through a single transfer port (of diameter about 0.6mm) into the internal conduit of the valve stem which communicates with an internal cavity in the valve stem block which generally includes a large sump.
- the formulation flows from the sump via a channel into a cone-shaped spray nozzle situated in the valve stem block and thereafter into the mouth piece of the actuator, whereby a user inhaling through the mouth piece will receive a metered dose of medicament containing formulation.
- a non-uniform flow path of large volume between the discharge port of valve stem and the mouth piece is therefore defined.
- the valve stem block contains a stray-producing means in the form of the conical nozzle (1).
- the propellant formulation undergoes rapid initial expansion at atmospheric pressure into the relatively large volume of the internal cavities of the valve stem and of the valve stem block to produce a range of different sizes of propellant droplets containing the medicament either in suspension or in solution.
- the diameter of the channel linked to the spray nozzle in conventional metered dose inhalers is generally low enough to create a constriction or bottleneck in the non-uniform flow path.
- the channel is 0.22mm or less in diameter so as to impose primary flow control and prevent the undesirable accumulation of larger droplets/particles. This narrow channel has the added benefit that the droplets/particles do not pass too quickly into the users mouth.
- a disadvantage of imposing primary flow control in this manner is that the channel is prone to blockage.
- Salbutamol HFA which is a suspension of Salbutamol in PI 34a containing about 10% ethanol
- the medicament accumulates at or near to the entrance and exit end of the channel.
- the build-up of material leads to a reduction in the effective dose dispensed.
- This effective dose can drop significantly over the lifetime of the metered dose inhaler (typically 200 to 300 doses).
- the present invention seeks to improve delivery of a pressurized formulation from a metered dose inhaler by locating spray-producing means in the flow path at or near to the outlet of the pressurized canister, rather than in the actuator. More particularly, the spray-producing means are located at or near to the outlet of the pressurized canister by having spray-producing means, e.g. in the form of a spray orifice, in the valve stem.
- spray-producing means e.g. in the form of a spray orifice
- an aerosol inhalation device comprising an actuator, canister containing pressurized aerosol formulation received in said actuator, the canister having a dispensing metering valve comprising a metering chamber, a valve stem disposed therein and movable between a charge position, in which the chamber is isolated from the atmosphere whilst the chamber communicates with the interior of the canister, and a discharge position, in which the contents of the chamber can be discharged to the atmosphere whilst the chamber is isolated from the canister, the valve stem having at least one transfer port, adapted to communicate with the chamber in the discharge position and a discharge port, adapted to engage valve stem location means in the actuator having a flow connection with the atmosphere, the stem including a flow conduit linking the at least one transfer port with the discharge port, such that the valve stem and the valve stem location means cooperate to form a continuous flow path, characterized in that the stem includes spray-producing means.
- a spray orifice located in the flow path at or near to the exit end of the pressurized canister eliminates the need for a narrow diameter channel in the valve stem block and permits a larger diameter discharge aperture in the vlave stem block than might otherwise been have expected for this type of arrangement.
- the spray-producing means may be in the form of a spray orifice located close to the transfer port of the valve stem, and in the flow path defined by the valve stem and the valve stem location means.
- the one or more transfer ports in the valve stem communicate with the spray orifice by means of a spray channel of substantially smaller diameter to the internal flow conduit of the valve stem.
- This channel may be, for example, less than 0.3mm, such as 0.2mm in diameter, so as to break up the pressurized liquid formulation into droplets.
- the valve stem may be provided with more than one transfer port, eg. two, substantially diametrically opposed to one another.
- the apertures are arranged in a substantially common radial plane of the valve stem. If there are more than two transfer ports, they are preferably arranged symmetrically so that the flow of formulation (which may be suspended or dissolved in the liquefied propellant) is effectively in the center of the flow path of the valve stem.
- the external aperture size transfer ports may be of conventional dimensions, (e.g. having a diameter of about 0.6mm).
- a transfer port may act as the spray-producing means, provided that it is sufficiently small to restrict the flow of formulation from the pressurized canister.
- transfer port When more than one transfer port acts as the spray-producing means, there are preferably at least two transfer ports arranged in a substantially common radial plane of the valve stem. In this alternative embodiment, there are preferably two transfer ports substantially diametrically opposed to one another. If there are more than two transfer ports, they are preferably arranged symmetrically so that the flow of formulation is mixed in the center of the flow conduit of the stem.
- the internal conduit of the valve stem tapers uniformly and inwardly from the end portion bearing the discharge port to the portion bearing the transfer port, for ease of moulding.
- the internal conduit may be essentially conical (e.g. a truncated cone).
- the diameter of the outermost bore (y) is preferably between x and lOx (where x is the diameter of the innermost bore).
- the diameter of the innermost bore (x) is 80% or less of the diameter of the outermost bore (y).
- the diameter of the innermost bore (x) is in the range of 40 to 80% of the diameter of the outermost bore (y).
- the transfer ports in the valve stem function as the spray- producing means they have a diameter of 0.12mm or more. In general, effect sprays are produced when the diameter is less than 0.4mm.
- valve stem location means is in the form of a valve stem block provided with a valve stem location portion, in which the valve stem makes a tight fit engagement and a dispensing portion, which is arranged to dispense atomized formulation to the user.
- valve stem engagement portion and the discharge portion are linked by a flow path which has a diameter greater than 0.22mm, (for example, 0.5 -2mm).
- the flow channel in the valve stem location means may form an L-shaped flow path with the valve stem.
- the two limbs of such an L-shaped flow path are at an angle of greater than 90°, e.g. about 115°.
- the two limbs of the flow path may be at an angle as great as 135° or more.
- the flow path defined by the valve stem and the valve location means need not be angled, and it is possible to have the flow path defined by the valve stem location means which is straight line.
- the cavity in the valve stem contains a shoulder upon which a portion of the wall at the first end of the valve stem is supported.
- the supported portion of the wall at the first end of the valve stem is a portion farthest away from the spray producing means.
- the actuator device is provided with a delivery outlet adapted to deliver the discrete amount of formulation to the user, said delivery outlet being in fluid communication with the dispensing portion of the valve stem location means.
- the outlet may be adapted for nasal delivery or preferably, with a mouthpiece for oral delivery to the lungs, via the pharynx.
- the dispensing portion of the valve stem location means may take any convenient shape such as a N-shape. In order to prevent rapid expansion and solid deposition on the walls of the dispensing portion, alternative shapes may be used such as W-shapes. Preferably the dispensing portion has curved internal walls to define a smooth flow path.
- valve stem as hereinbefore defined.
- actuator for use in association with a pressurized container having a metering valve as hereinbefore defined.
- the actuator comprises a valve stem location means capable of engaging a valve stem of a pressurised container such that the valve stem and the valve stem location means cooperate to form a continuous flow path.
- the methods for manufacturing the components parts of the invention will be familiar to those skilled in the art.
- injection moulding may be used to make the valve stem.
- the internal conduit of the valve stem will be larger than the internal conduit of conventional valve stems of this invention.
- the spray-producing means is combined with the transfer ports, the internal conduits of the transfer ports will generally be smaller relative to those described in the prior art, which will necessitate the use of smaller diameter side pins.
- the moulding stem pin will generally be larger than used relative to the prior art.
- two supporting side pins may be used to grip the stem pin whilst forming twin apertures.
- the stem and side pins are made from any suitable material such as steel.
- the metered dose inhaler of the invention may be of the manually operable or breath actuated type. It is envisaged that the invention may be used primarily in conjunction with the delivery of a medicament in the form of a propellant solution, dispersion or (preferably) suspension or in the form of a dry powder. It is thought that pulmonary inhalation would be the primary application of the invention either nasally or (preferably) orally and the delivery outlet of the actuator device may be adapted accordingly.
- the present invention could be used to deliver medicaments including antiallergics, analgesics, bronchodilators, antihistamines, therapeutic proteins and peptides, antitussives, anginal preparations, antibiotics, anti-inflammatory preparations, hormones, or sulfonamides (such as for example a vasoconstrictive amine, an enzyme, an alkaloid, or a steroid and synergistic combinations of these).
- medicaments including antiallergics, analgesics, bronchodilators, antihistamines, therapeutic proteins and peptides, antitussives, anginal preparations, antibiotics, anti-inflammatory preparations, hormones, or sulfonamides (such as for example a vasoconstrictive amine, an enzyme, an alkaloid, or a steroid and synergistic combinations of these).
- medicaments which may be employed are: Isoproterenol [alpha (isopropylaminomethyl) protocatechuyl alcohol], phenylephrine, phenylpropanolamine, glucagon, adrenochrome, trypsin, epinephrine, ephedrine, narcotine, codeine, atropine, heparin, morphine, dihydromorphinone, ergotamine, scopolamine, methapyrilene, cyanocobalamin, terbutaline, rimiterol, salbutamol, flunisolide, colchicine, pirbuterol, beclomethasone, orciprenaline, fentanyl, and diamorphine.
- Isoproterenol alpha (isopropylaminomethyl) protocatechuyl alcohol
- phenylephrine phenylpropanolamine
- glucagon adrenochrome
- antibiotics such as neomycin, streptomycin, penicillin, procaine penicillin, tetracycline, chlorotetracycline and hydroxytetracycline
- adrenocorticotropic hormones and adrenocortical hormones such as cortisone, hydrocortisone, hydrocortisone acetate and prednisolone
- insulin and antiallergy compounds such as cromolyn sodium
- the formulation comprises: salbutamol together with a propellant and optionally one or more additives.
- the formulation comprises salbutamol and P134a (especially preferably with about 10wt% ethanol).
- Figure 1 is a partially truncated vertical section of an aerosol actuator according to the invention fitted with a pressurized medicament canister;
- Figure 2 is a metering valve according to the invention, shown in vertical section and;
- Figure 3 are alternative embodiments of valve stems according to the invention, shown in partially truncated vertical section.
- an aerosol inhalation actuator comprises a generally cylindrical housing (1) having a mouth piece (2) angled at about 115° to the perpendicular axis of the cylindrical housing (1).
- the housing (1) receives a cylindrical canister (3) of pressurized medicament, the canister (3) being provided at one end with a metering valve including a valve stem (4).
- the valve stem (4) is located in, by means of a tight fit engagement, in a cavity in a valve stem location means in the form of a valve stem block (5) extending upwardly from the closed base of the cylindrical housing (1).
- the valve stem block (5) encloses a channel (7) communicating with the reception cavity (6) and terminating in a discharge exit opposite the mouth piece (2), such that the valve stem (4) and the valve stem block (5) cooperate to form a generally L-shaped continuous flow path.
- the discharge exit (8) of channel (7) is tapers putwards with respect to the overall cross-section of channel (7), and typically is of a diameter in the range 0.5-2mm.
- Naive stem (4) has a substantially cylindrical main body with a pair of diametrically disposed transfer ports (9,10) located adjacent to and just outside the canister (3), when the canister is in the charge position.
- the valve stem (4) encloses a uniformly tapering internal conduit (11) extending, at its narrow end, from the region of the transfer ports (9,10) and terminating with the discharge port (12) of the valve stem, which is located in the valve stem block (5).
- the discarge end portion of the valve stem (4) is partially seated on an internal shoulder (13) in the reception cavity (6).
- the transfer ports (9,10) are in the form of cylindrical apertures in the outer surface of the valve stem (4), each transfer port after an initially cylindrical cross-section tapers down to cylindrical channels (14,15) in moving towards the center of the valve stem, the ports (9,10) and channels (14,15) acting as a spray-producing means in the form of opposed spray orifices.
- the ports (9,10) channels (14,15) internal conduit (11) and stem block channel (7) cooperate to form a continuous flow path.
- Axial movement of the canister (3) relative to the valve stem 4 and towards the stem block (5) permits transfer ports (9,10) to enter the metering valve in the canister (3).
- a metered amount of pressurized formulation passes through ports (9,10) and into the innermost ends of the channels (14,15) in the valve stem (4).
- the two streams of formulation are atomized and interfere to such an extent that the combined flow is slowed relative to its initial velocity.
- the formulation passes out of the discharge exit (8) in the valve stem block and delivers the formulation through the mouth piece (2) to the user.
- a metering valve according to the invention comprises a body in the form of a circular cup (21) fitted in a ferrule (22).
- the metering chamber (24) is provided at the outer end, immediately adjacent to the field (22) with an outer seal or gasket (25), and at the inner end with an inner seal or gasket (26).
- the inner end of the chamber (24) is adapted to fit within the interior of a pressurized aerosol canister.
- a hollow tubular guide (27) extends from the cup 20 beneath the chamber (24) and inner seal (26).
- the side walls of the guide (27) are additionally provided with diametrically opposed elongate aperatures (not shown).
- the lower end portion of the guide (27) is provided with an inwardly facing peripheral flange (28).
- a valve member in the form of a valve stem (29) of generally circular cross- section extends through the chamber (24) and into the interior of the guide (27).
- the end portion of the valve stem extending into the guide (27) is surrounded by a compression spring (30), retained in the guide (27) by the flange (28), and bearing against an annular collar (31) mounted on the inner end portion of the valve stem (29).
- the collar (31) is slidably mounted within the guide (27).
- the spring (30) urges the valve stem (29) towards the inoperative position shown in Figure 2.
- the outwards movement of the valve stem (29) is limited by a peripheral rib (32) extending from the stem (29) within the metering chamber (24), which bears against the outer seal (25) when the valve is in the inoperative position.
- the rib (32) also limits the inwards movement of the valve stem (29) by bearing against the base of the bush (23) when the valve stem is in the operative (discharge) position.
- the lower portion of the valve stem (29) is provided with means for the communicating the chamber (24) with the interior in the form of a plurality of channels (33) when the valve stem (29) is in the inoperative position.
- the channels (33) are arranged such that when the stem (29) is in the inoperative position, they terminate just above the inner seal (26), within the base of the bush (23).
- the outer end portion of the valve stem (29) is provided with an outlet conduit (35) through which a charge can be dispensed from the metering chamber (24), such charge entering the outlet conduit (35) through diametrically opposed transfer ports (36, 37) located on the valve stem (29) and lying outside the metering chamber (24) when the valve is in the inoperative (charge) position (as shown).
- the entrance of the transfer ports in the outer wall of the valve stem (29) are cylindrical in cross-section, but on moving towards the center of the valve stem taper towards spray channels
- the transfer ports (36, 37), channels (38, 39), and internal conduit (35) form a continuous flow path through which a charge can be dispensed from the metering chamber (24), such charge entering the outlet conduit (35) via the transfer ports (36, 37).
- the transfer ports lie outside the ferrule (22), and communicate with the chamber (24), on inward movement of the stem (29) to the operative (discharge) position.
- the stem (29) forms a sealing fit with the outer seal (25) in both the operative and inoperative positions, and a sealing fit with inner seal (26) only when the valve is in the operative position.
- the chamber (24) in the inoperative position, is sealed from the outside (the atmosphere), but is adapted to communicate with the interior of the container, and in the operative position communicates with the outside, while being sealed from the interior.
- valve In use, the valve is crimped onto a cylindrical canister for pressurized aerosol material, eg a medicament formulation, the container bearing against the container gasket (40). In the inoperative position, the pressurized material can readily move from the chamber (24) to the interior of the container, and vice versa, by means of the channels (33).
- pressurized aerosol material eg a medicament formulation
- valve stem (29) With the valve inverted, ie with the outer dispensing portion of the valve stem (29) pointing downwards, the chamber fills with pressurized liquid propellant. Actuation of the valve stem (29), against the bias of the spring
- a valve stem (51) is provided with an internal conduit (52) connecting the discharge end of the stem (53) with a transfer port (54) radially disposed towards the opposing end of the stem.
- Figure 3(b) illustrates a valve which is similar to that illustrated in Figure 3(a) save that two transfer ports (57, 58) are diametrically disposed across a valve stem (59), to form a single through going channel.
- Figure 3(c) is a vertical section through the valve stem of Figure 3 A along the lines I-I.
- spray-producing means are formed in a valve stem (62) having an internal conduit (63), by having radially disposed transfer ports (64, 65) which intersect with the non-discharge portion of the internal conduit.
- a metered amount of formulation passes through transfer ports (64.65) into the innermost end of the tapered internal conduit (63) of the valve stem(62).
- the two streams of formulation interfere to such as extent that a spray is produced in the region of the non-discharge portion (66) of the conduit (63).
Landscapes
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dispersion Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Anesthesiology (AREA)
- Chemical & Material Sciences (AREA)
- Mechanical Engineering (AREA)
- Hematology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Containers And Packaging Bodies Having A Special Means To Remove Contents (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2002222110A AU2002222110A1 (en) | 2000-11-28 | 2001-11-28 | Improved metering valve and actuator for metered dose inhaler |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0028943.9 | 2000-11-28 | ||
GBGB0028943.9A GB0028943D0 (en) | 2000-11-28 | 2000-11-28 | Device |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2002043794A1 true WO2002043794A1 (en) | 2002-06-06 |
WO2002043794A9 WO2002043794A9 (en) | 2003-05-08 |
Family
ID=9903994
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2001/005297 WO2002043794A1 (en) | 2000-11-28 | 2001-11-28 | Improved metering valve and actuator for metered dose inhaler |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU2002222110A1 (en) |
GB (1) | GB0028943D0 (en) |
WO (1) | WO2002043794A1 (en) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006021797A1 (en) * | 2004-08-26 | 2006-03-02 | Bespak Plc | Improvements in metering valves for pressurised dispensing containers |
WO2010072064A1 (en) * | 2008-12-26 | 2010-07-01 | 东莞怡信磁碟有限公司 | Portable chargeable spraying bottle |
EP2144653A4 (en) * | 2007-05-10 | 2011-06-29 | 3M Innovative Properties Co | MANUFACTURING VALVE COMPONENTS |
US8695896B2 (en) | 2011-11-23 | 2014-04-15 | Zhejiang Jm Industry Co., Ltd. | Perfume atomizer |
US8881775B2 (en) | 2004-04-20 | 2014-11-11 | Beauty Union Global Limited | Refill perfume bottle |
CN104225739A (en) * | 2014-09-30 | 2014-12-24 | 四川普锐特医药科技有限责任公司 | Medical quantitative inhalation aerosol |
US9146144B2 (en) | 2011-07-26 | 2015-09-29 | Dongguan Yixin Magnetic Disk Co., Ltd. | Portable refillable cream dispenser |
WO2015169974A1 (en) * | 2014-05-09 | 2015-11-12 | Norton (Waterford) Limited | Aerosol device |
US9365408B2 (en) | 2012-11-16 | 2016-06-14 | Zhejiang Jm Industry Co., Ltd. | Auto refill perfume atomizer |
US9592355B2 (en) | 2005-09-09 | 2017-03-14 | Raymond John Bacon | Dispenser |
US9707360B2 (en) | 2004-11-19 | 2017-07-18 | Clinical Designs Limited | Substance source |
US9987441B2 (en) | 2009-03-10 | 2018-06-05 | Euro-Celtique S.A. | Counter |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2534957B1 (en) | 2007-12-14 | 2015-05-27 | AeroDesigns, Inc | Delivering aerosolizable products |
GB0904059D0 (en) | 2009-03-10 | 2009-04-22 | Euro Celtique Sa | Counter |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1042142A (en) * | 1961-10-13 | 1966-09-14 | Speciality Valves Ltd | Improvements in discharge control valves for fluids |
EP0360463A2 (en) * | 1988-09-10 | 1990-03-28 | FISONS plc | Inhalation devices with a reduced risk of blockage |
EP0448204A1 (en) * | 1990-02-20 | 1991-09-25 | Pauline L. Dessertine | Inhaler device with counter and timer means |
US5482030A (en) * | 1994-06-13 | 1996-01-09 | Klein; David | Aerosol and non-aerosol spray counter |
EP0692434A2 (en) * | 1994-07-14 | 1996-01-17 | V.A.R.I. S.p.A. | Aerosol metering valves |
US5894964A (en) * | 1994-09-23 | 1999-04-20 | Chesebrough-Pond's Usa Co., | Aerosol |
-
2000
- 2000-11-28 GB GBGB0028943.9A patent/GB0028943D0/en not_active Ceased
-
2001
- 2001-11-28 AU AU2002222110A patent/AU2002222110A1/en not_active Abandoned
- 2001-11-28 WO PCT/GB2001/005297 patent/WO2002043794A1/en not_active Application Discontinuation
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1042142A (en) * | 1961-10-13 | 1966-09-14 | Speciality Valves Ltd | Improvements in discharge control valves for fluids |
EP0360463A2 (en) * | 1988-09-10 | 1990-03-28 | FISONS plc | Inhalation devices with a reduced risk of blockage |
EP0448204A1 (en) * | 1990-02-20 | 1991-09-25 | Pauline L. Dessertine | Inhaler device with counter and timer means |
US5482030A (en) * | 1994-06-13 | 1996-01-09 | Klein; David | Aerosol and non-aerosol spray counter |
EP0692434A2 (en) * | 1994-07-14 | 1996-01-17 | V.A.R.I. S.p.A. | Aerosol metering valves |
US5894964A (en) * | 1994-09-23 | 1999-04-20 | Chesebrough-Pond's Usa Co., | Aerosol |
Cited By (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8881775B2 (en) | 2004-04-20 | 2014-11-11 | Beauty Union Global Limited | Refill perfume bottle |
US7959042B2 (en) | 2004-08-26 | 2011-06-14 | Consort Medical Plc | In metering valves for pressurised dispensing containers |
WO2006021797A1 (en) * | 2004-08-26 | 2006-03-02 | Bespak Plc | Improvements in metering valves for pressurised dispensing containers |
CN101031484B (en) * | 2004-08-26 | 2010-12-01 | 贝斯帕克有限公司 | Metering valves for use with pressurized dispensing containers |
US9707360B2 (en) | 2004-11-19 | 2017-07-18 | Clinical Designs Limited | Substance source |
US9592355B2 (en) | 2005-09-09 | 2017-03-14 | Raymond John Bacon | Dispenser |
US10369307B2 (en) | 2005-09-09 | 2019-08-06 | Clinical Designs Limited | Dispenser |
EP2144653A4 (en) * | 2007-05-10 | 2011-06-29 | 3M Innovative Properties Co | MANUFACTURING VALVE COMPONENTS |
US20170197247A1 (en) * | 2007-05-10 | 2017-07-13 | 3M Innovative Properties Company | Manufacture of Metered Dose Valve Components |
US8978938B2 (en) | 2008-12-26 | 2015-03-17 | Dongguan Yixin Magnetic Disk Co., Ltd. | Portable chargeable spray bottle |
US10246249B2 (en) | 2008-12-26 | 2019-04-02 | Dongguan Yixin Magnetic Disk Co., Ltd | Portable chargeable spray bottle |
WO2010072064A1 (en) * | 2008-12-26 | 2010-07-01 | 东莞怡信磁碟有限公司 | Portable chargeable spraying bottle |
US9738437B2 (en) | 2008-12-26 | 2017-08-22 | Dong-Guan Yixin Magnetic Disc Co., Ltd | Portable chargeable spray bottle |
US9987441B2 (en) | 2009-03-10 | 2018-06-05 | Euro-Celtique S.A. | Counter |
US9146144B2 (en) | 2011-07-26 | 2015-09-29 | Dongguan Yixin Magnetic Disk Co., Ltd. | Portable refillable cream dispenser |
US8695896B2 (en) | 2011-11-23 | 2014-04-15 | Zhejiang Jm Industry Co., Ltd. | Perfume atomizer |
US9365408B2 (en) | 2012-11-16 | 2016-06-14 | Zhejiang Jm Industry Co., Ltd. | Auto refill perfume atomizer |
WO2015169974A1 (en) * | 2014-05-09 | 2015-11-12 | Norton (Waterford) Limited | Aerosol device |
US10960154B2 (en) | 2014-05-09 | 2021-03-30 | Norton (Waterford) Limited | Aerosol device |
CN104225739A (en) * | 2014-09-30 | 2014-12-24 | 四川普锐特医药科技有限责任公司 | Medical quantitative inhalation aerosol |
Also Published As
Publication number | Publication date |
---|---|
GB0028943D0 (en) | 2001-01-10 |
WO2002043794A9 (en) | 2003-05-08 |
AU2002222110A1 (en) | 2002-06-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1591137B1 (en) | Apparatus for delivering aerosolized medication | |
AU777562B2 (en) | Internal vortex mechanism for inhaler device | |
US5115803A (en) | Aerosol actuator providing increased respirable fraction | |
WO2002043794A1 (en) | Improved metering valve and actuator for metered dose inhaler | |
EP0546009B1 (en) | Aerosol actuator providing increased respirable fraction | |
KR20070073865A (en) | Dispensers, Storage Units and Powder Dispensing Methods | |
US20100147293A1 (en) | Aerosol actuator | |
JPH11501892A (en) | Aerosol valve | |
JPS5819268A (en) | Inhalator of drug | |
AU759709B2 (en) | Improvements in drug delivery devices | |
JP2018532564A (en) | Canisters, valves, and metered dose inhalers | |
AU2001253667A1 (en) | Respiratory equipment spacer assembly | |
CA2407320A1 (en) | Respiratory equipment spacer assembly | |
EP4126138B1 (en) | Aerosol delivery of at least two liquid compositions | |
JP2023532948A (en) | Oral dispenser for liquids, especially nicotine or cannabis containing liquids | |
AU776816B2 (en) | Method and apparatus for delivering aerosolized medication | |
US7942146B2 (en) | Impaction nozzle for propellant driven metered dose aerosols | |
HK40084749B (en) | Aerosol delivery of at least two liquid compositions | |
HK40084749A (en) | Aerosol delivery of at least two liquid compositions | |
HK1065964B (en) | An improved aerosol actuator | |
HK1153688A (en) | Inhaler |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
COP | Corrected version of pamphlet |
Free format text: PAGES 1/3-3/3, DRAWINGS, REPLACED BY NEW PAGES 1/3-3/3; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |